REPLIGEN CORP Intangible Assets, Net (Excluding Goodwill)
REPLIGEN CORP (RGEN) had Intangible Assets, Net (Excluding Goodwill) of $357.62 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-07-29
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $357.62M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $368.19M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $386.15M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $395.44M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $357.62M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $368.19M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $386.15M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $395.44M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $406.21M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $409.23M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $397.90M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $380.75M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $386.05M 10-Q/A · filed 2024-11-18 | $379.81M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $394.50M 10-Q/A · filed 2024-11-18 | $388.15M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $406.96M 10-K · filed 2025-03-14 | $400.49M 10-K · filed 2024-02-22 |
| 2023-09-30 | $350.32M 10-Q/A · filed 2024-11-18 | $343.73M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $358.41M 10-Q/A · filed 2024-11-18 | $351.70M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $353.42M 10-Q/A · filed 2024-11-18 | $346.60M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $360.62M 10-Q/A · filed 2024-11-18 | $353.68M 10-K · filed 2023-02-22 |
| 2022-09-30 | $359.56M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $322.21M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $329.93M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $337.27M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $340.16M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $276.55M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $281.67M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $287.10M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $215.38M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $204.74M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $208.53M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $212.55M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $216.29M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $220.48M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $132.65M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $135.44M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $136.53M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $139.18M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $142.27M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $144.75M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $147.42M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $29.01M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $29.22M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $29.81M 10-K · filed 2018-02-22 | |
| 2016-09-30 | $18.67M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $19.19M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $12.46M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $12.76M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $13.15M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $13.59M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $13.88M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $14.64M 10-K · filed 2016-02-25 | $14.64M 10-K · filed 2015-03-17 |
| 2014-09-30 | $15.35M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $16.12M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $5.92M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $6.19M 10-K · filed 2015-03-17 | |
| 2013-09-30 | $6.48M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $6.50M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $6.91M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $7.18M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $7.38M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $7.18M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $7.81M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $7.80M 10-K · filed 2013-03-15 | |
| 2011-09-30 | $1.13M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $1.18M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $1.22M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |